Beam Therapeutics Inc. (BEAM)
Price:
27.00 USD
( + 1.87 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
NEWS
Top Stock Pick Report: A Q3 For the Record Books
schaeffersresearch.com
2025-10-07 12:25:33Subscribers to Chart of the Week received this commentary on Sunday, October 5.
JIM BEAM AND THE CADILLAC FORMULA 1® TEAM ANNOUNCE GLOBAL PARTNERSHIP, FUELING A VISION TO REACH NEW AUDIENCES
prnewswire.com
2025-09-17 07:00:00Two American originals united on one world stage CLERMONT, Ky. and FISHERS, Ind.
Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript
seekingalpha.com
2025-09-03 20:38:18Beam Therapeutics Inc. (NASDAQ:BEAM ) Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants John Evans - CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President All right. Good afternoon.
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
zacks.com
2025-08-28 09:51:06CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
globenewswire.com
2025-08-25 07:00:00CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m.
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
globenewswire.com
2025-08-14 07:00:00CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
zacks.com
2025-08-06 12:56:09Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
2025-08-05 09:16:20Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.11 per share a year ago.
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
globenewswire.com
2025-08-05 07:00:00With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
zacks.com
2025-07-29 11:05:31Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?
zacks.com
2025-07-10 11:05:17Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
fool.com
2025-06-28 09:10:00There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
3 Promising Genomics Stocks to Keep an Eye On in 2025
zacks.com
2025-06-27 09:06:12Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Top Stock Pick Report: V-Shaped Rallies Everywhere
schaeffersresearch.com
2025-06-24 10:42:27Subscribers to Chart of the Week received this commentary on Sunday, June 22.
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases
seekingalpha.com
2025-06-20 10:07:49Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from phase 1/2 BEACON study using BEAM-101, expected in the 2nd half of 2025. The global sickle cell disease market is expected to reach $12.38 billion by 2032.
Top Stock Pick Report: A Q3 For the Record Books
schaeffersresearch.com
2025-10-07 12:25:33Subscribers to Chart of the Week received this commentary on Sunday, October 5.
JIM BEAM AND THE CADILLAC FORMULA 1® TEAM ANNOUNCE GLOBAL PARTNERSHIP, FUELING A VISION TO REACH NEW AUDIENCES
prnewswire.com
2025-09-17 07:00:00Two American originals united on one world stage CLERMONT, Ky. and FISHERS, Ind.
Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript
seekingalpha.com
2025-09-03 20:38:18Beam Therapeutics Inc. (NASDAQ:BEAM ) Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants John Evans - CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President All right. Good afternoon.
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
zacks.com
2025-08-28 09:51:06CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
globenewswire.com
2025-08-25 07:00:00CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m.
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
globenewswire.com
2025-08-14 07:00:00CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
zacks.com
2025-08-06 12:56:09Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
2025-08-05 09:16:20Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.11 per share a year ago.
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
globenewswire.com
2025-08-05 07:00:00With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
zacks.com
2025-07-29 11:05:31Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?
zacks.com
2025-07-10 11:05:17Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
fool.com
2025-06-28 09:10:00There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
3 Promising Genomics Stocks to Keep an Eye On in 2025
zacks.com
2025-06-27 09:06:12Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Top Stock Pick Report: V-Shaped Rallies Everywhere
schaeffersresearch.com
2025-06-24 10:42:27Subscribers to Chart of the Week received this commentary on Sunday, June 22.
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases
seekingalpha.com
2025-06-20 10:07:49Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from phase 1/2 BEACON study using BEAM-101, expected in the 2nd half of 2025. The global sickle cell disease market is expected to reach $12.38 billion by 2032.